Drug intelligence / Profile preview

XC101-D13H

Development stage: Phase 1
Lead developer: Xoc Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

XC101-D13H is an oral therapy being developed by Xoc Pharmaceuticals for the prevention of migraine. It has a novel mechanism of action targeting multiple serotonin receptors. The drug acts as an antagonist at 5-HT2B, 5-HT2C, and 5-HT2A receptors, while functioning as a partial agonist at 5-HT1B, 5-HT1D, and 5-HT1F receptors, and as an agonist at 5-HT7 receptors. This receptor profile was designed to provide therapeutic benefit for migraine prevention while avoiding common serotonergic agonist-driven side effects.

Targets

HTR1B (5-Hydroxytryptamine Receptor 1B)HTR2A (Serotonin receptor 5-HT2A)HTR7 (5-hydroxytryptamine receptor 7)HTR1D (5-hydroxytryptamine receptor 1D)HTR2C (5-hydroxytryptamine 2C receptor)HTR1F (Serotonin 5-HT1F receptor)HTR2B (5-Hydroxytryptamine Receptor 2B)

Beyond the preview

Go deeper on XC101-D13H.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XC101-D13H.

Explore the full profile